Clinical outcomes after peripheral blood stem cell donation by related donors: A Dutch single-center cohort study

Transfusion

Volumn 53, Issue 1, 2013, Pages 96-103

  Wiersum Osselton, Johanna C ^a   Van Walraven, Suzanna M ^a   Bank, Ivan ^a   Lenselink, A Mariëtte ^a   Fibbe, Willem E ^a   Van Der Bom, Johanna G ^a   Brand, Anneke ^a  

^a CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEOPLASM; ORGAN DONOR; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE PAIN; QUESTIONNAIRE; RETROSPECTIVE MEMORY; SEX DIFFERENCE; STEM CELL MOBILIZATION; SURGICAL RISK; SURGICAL TECHNIQUE; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 85027949769     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03676.x     Document Type: Article

References (23)

1. Sacchi N, Costeas P, Hartwell L, Hruley CK, Raffoux C, Rosenmayr A, Greinix H,; Quality Assurance and Clinical Working Groups of the World Marrow Donor Association. Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health. Bone Marrow Transplant 2008; 42: 9-14.
2. Siddiq S, Pamphilon D, Brunskill S, Doree C, Hyde C, Stanworth S,. Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors. Cochrane Database Syst Rev 2009;(1):CD006406.
3. D'Souza A, Jaiyesimi I, Trainor L, Venuturumili P,. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev 2008; 22: 280-90.
4. Dincer AP, Gottschall J, Margolis DA,. Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. J Pediatr Hematol Oncol 2004; 26: 761-3.
5. Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A,. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (G-CSF). A case report and review of the literature. Haematologica 2006; 91 (Suppl): ECR08.
6. Arimura K, Inoue H, Kukita T, Matsushita K, Akimot M, Kawamata N, Yamaguchi A, Kawada H, Ozak A, Arima N, Tei C,. Acute lung injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone. Haematologica 2005; 90: ECR10.
7. Huttmann A, Duhrsen U, Stypmann J, Noppeney R, Nuckel H, Neumann T, Gutersohn A, Nikol S, Erbel R,. Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure-feasibility, safety and effects on exercise tolerance and cardiac function. Basic Res Cardiol 2006; 101: 78-86.
8. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G, Baldomero H, Niederwieser D, Apperley JF, Gratwohl A,. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94-101.
9. Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, Howe C, Leitman S, Horowitz M, Gluckman E, Rowley S, Przepiorka D, Champlin R,. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903-8.
10. Freedman MH, Bonilla MA, Fier C, Bolyard AA, Scarlata D, Boxer LA, Brown S, Cham B, Kannourakis G, Kinsey SE, Mori PG, Cottle T, Welte K, Dale DC,. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000; 96: 429-36.
11. Socie G, Mary JY, Schrezenmeier H, Marsh J, Bacigalupo A, Locasciulli A, Fuehrer M, Bekassy A, Tichelli A, Passweg J,. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 109: 2794-6.
12. Dale DC, Bolyard AA, Schwinzer BG, Pracht G, Bonilla MA, Boxer L, Freedman MH, Donadieu J, Kannourakis G, Alter BP, Cham BP, Winkelstein J, Kinsey SE, Zeidler C, Welte K., The Severe Chronic Neutropenia International Registry: 10-year follow-up report. Support Cancer Ther 2006; 3: 220-31.
13. Confer DL, Miller JP,. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 77-8.
14. Hölig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH, Rutt C, Ehninger G,. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757-63.
15. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, Leitman SF, Anderlini P, Haagenson MD, Kurian S, Klein JP, Horowitz MM, Confer DL,. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604-11.
16. Leitner GC, Baumgartner K, Kalhs P, Biener D, Greinix HT, Hoecker P, Worel N,. Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study. Bone Marrow Transplant 2009; 43: 357-63.
17. de la Rubia J, de Arriba F, Arbona C, Pascual MJ, Zamora C, Insunza A, Martinez D, Paniagua C, Diaz MA, Sanz MA,. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008; 93: 735-40.
18. National Marrow Donor Program. Assessment Tool at Workup. Document A00262 revision 7 (10/2009).
19. Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM,. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 2001; 27: 689-92.
20. Hasenclever D, Sextro M,. Safety of alloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17 (Suppl 2): S28-S30.
21. Martino M, Console G, Dattola A, Callea I, Messina G, Moscato T, Massara E, Irrera G, Fedele R, Gervasi A, Bresolin G, Iacopino P,. Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. Bone Marrow Transplant 2009; 44: 163-8.
22. Shaw BE, Ball L, Beksac M, Bengtsson M, Confer D, Diler S, Fechter M, Greinix H, Koh M, Lee S, Nicoloso-De-Faveri G, Philippe J, Pollichieni S, Pulsipher M, Schmidt A, Yang E, van Walraven AM,; Clinical Working Group; Ethics Working Group of the WMDA. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. Bone Marrow Transplant 2010; 45: 832-8.
23. van Walraven SM, Nicoloso-de Faveri G, Axdorph-Nygell UAI, Douglas KW, Jones DA, Lee SJ, Pulsipher M, Ritchie L, Halter J, Shaw BE,; WMDA Ethics and Clinical working groups. Family donor care management: principles and recommendations. Bone Marrow Transplant 2010; 45: 1269-73.